Research ExplorerPublicationsA systematic review on the clinical benefit and role of radi...

A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases.

Standard

A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. / Stang, Axel; Fischbach, Roman; Teichmann, Wolfgang; Bokemeyer, Carsten; Braumann, Dietrich.

In: EUR J CANCER, Vol. 45, No. 10, 10, 2009, p. 1748-1756.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Stang, A, Fischbach, R, Teichmann, W, Bokemeyer, C & Braumann, D 2009, 'A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases.', EUR J CANCER, vol. 45, no. 10, 10, pp. 1748-1756. <http://www.ncbi.nlm.nih.gov/pubmed/19356924?dopt=Citation>

APA

Stang, A., Fischbach, R., Teichmann, W., Bokemeyer, C., & Braumann, D. (2009). A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. EUR J CANCER, 45(10), 1748-1756. [10]. http://www.ncbi.nlm.nih.gov/pubmed/19356924?dopt=Citation

Vancouver

Stang A, Fischbach R, Teichmann W, Bokemeyer C, Braumann D. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. EUR J CANCER. 2009;45(10):1748-1756. 10.

Bibtex

@article{333cd5e9c49e406db6c2dbdd16c473dd,
title = "A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases.",
abstract = "AIM: To evaluate the role of radiofrequency ablation (RFA) as treatment of colorectal cancer liver metastases (CLMs). METHOD: A PubMed literature search for original articles published until August 2008 was performed. Studies with 40 patients, 18 month median follow-up and reported 3 year overall survival (OS) rates after RFA of CLM were selected for analysis. RESULTS: Thirteen clinical series and 8 non-randomised comparative studies were analysed. Median progression free survival after RFA ranged between 6 and 13 months. Median and 5-year OS after RFA (RFA plus resection) ranged between 24-59 months and 18-40% (36-46 months and 27-30%). Comparative studies indicated significantly improved OS after RFA versus chemotherapy alone, RFA plus chemotherapy versus RFA alone and up-front RFA versus RFA following second-line chemotherapy. CONCLUSION: Our findings support that RFA prolongs time without toxicity and survival as an adjunct to hepatectomy and/or chemotherapy in well-selected patients, but not as an alternative to resection.",
author = "Axel Stang and Roman Fischbach and Wolfgang Teichmann and Carsten Bokemeyer and Dietrich Braumann",
year = "2009",
language = "Deutsch",
volume = "45",
pages = "1748--1756",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "10",

}

RIS

TY - JOUR

T1 - A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases.

AU - Stang, Axel

AU - Fischbach, Roman

AU - Teichmann, Wolfgang

AU - Bokemeyer, Carsten

AU - Braumann, Dietrich

PY - 2009

Y1 - 2009

N2 - AIM: To evaluate the role of radiofrequency ablation (RFA) as treatment of colorectal cancer liver metastases (CLMs). METHOD: A PubMed literature search for original articles published until August 2008 was performed. Studies with 40 patients, 18 month median follow-up and reported 3 year overall survival (OS) rates after RFA of CLM were selected for analysis. RESULTS: Thirteen clinical series and 8 non-randomised comparative studies were analysed. Median progression free survival after RFA ranged between 6 and 13 months. Median and 5-year OS after RFA (RFA plus resection) ranged between 24-59 months and 18-40% (36-46 months and 27-30%). Comparative studies indicated significantly improved OS after RFA versus chemotherapy alone, RFA plus chemotherapy versus RFA alone and up-front RFA versus RFA following second-line chemotherapy. CONCLUSION: Our findings support that RFA prolongs time without toxicity and survival as an adjunct to hepatectomy and/or chemotherapy in well-selected patients, but not as an alternative to resection.

AB - AIM: To evaluate the role of radiofrequency ablation (RFA) as treatment of colorectal cancer liver metastases (CLMs). METHOD: A PubMed literature search for original articles published until August 2008 was performed. Studies with 40 patients, 18 month median follow-up and reported 3 year overall survival (OS) rates after RFA of CLM were selected for analysis. RESULTS: Thirteen clinical series and 8 non-randomised comparative studies were analysed. Median progression free survival after RFA ranged between 6 and 13 months. Median and 5-year OS after RFA (RFA plus resection) ranged between 24-59 months and 18-40% (36-46 months and 27-30%). Comparative studies indicated significantly improved OS after RFA versus chemotherapy alone, RFA plus chemotherapy versus RFA alone and up-front RFA versus RFA following second-line chemotherapy. CONCLUSION: Our findings support that RFA prolongs time without toxicity and survival as an adjunct to hepatectomy and/or chemotherapy in well-selected patients, but not as an alternative to resection.

M3 - SCORING: Zeitschriftenaufsatz

VL - 45

SP - 1748

EP - 1756

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

IS - 10

M1 - 10

ER -